We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+8.01%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$20.1B
AUM Growth
+$3.5B
Cap. Flow
+$2.5B
Cap. Flow %
12.41%
Top 10 Hldgs %
33.13%
Holding
257
New
120
Increased
40
Reduced
39
Closed
20

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$546M
2
WTW icon
Willis Towers Watson
WTW
+$471M
3
MA icon
Mastercard
MA
+$344M
4
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$240M
5
BBL
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
+$238M

Top Sells

Rank Stock Value
1
TIF
Tiffany & Co.
TIF
+$301M
2
NYT icon
New York Times
NYT
+$209M
3
V icon
Visa
V
+$194M
4
ELV icon
Elevance Health
ELV
+$145M
5
ABBV icon
AbbVie
ABBV
+$123M

Sector Composition

Rank Sector Weight
1 Healthcare 34.84%
2 Financials 13.62%
3 Communication Services 11.15%
4 Technology 9.41%
5 Industrials 7.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SHW icon
26
Sherwin-Williams
SHW
$89.8B
$292M 1.45%
1,185,423
+17,325
+1% +$4.13M
TRU icon
27
TransUnion
TRU
$15.3B
$284M 1.41%
3,160,077
+1,425,995
+82% +$129M
CHTR icon
28
Charter Communications
CHTR
$18.2B
$280M 1.39%
454,178
-92,753
-17% -$58M
GWPH
29
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$277M 1.38%
+1,278,900
New +$240M
V icon
30
Visa
V
$677B
$277M 1.38%
1,308,829
-919,275
-41% -$194M
MXIM
31
DELISTED
Maxim Integrated Products
MXIM
$270M 1.34%
2,957,400
+1,415,000
+92% +$130M
AMRS
32
DELISTED
Amyris Inc.
AMRS
$258M 1.28%
13,500,000
-4,000,000
-23% -$58M
EXEL icon
33
Exelixis
EXEL
$13.4B
$243M 1.21%
10,750,000
-250,000
-2% -$5.65M
HLT icon
34
Hilton Worldwide
HLT
$71.5B
$236M 1.17%
1,949,437
+309,000
+19% +$35.7M
BBL
35
DELISTED
BHP Group Plc American Depositary Shares (Each representing two Ordinary Shares)
BBL
$231M 1.15%
+4,000,521
New +$238M
EDU icon
36
New Oriental
EDU
$8.98B
$223M 1.11%
1,594,300
+440,000
+38% +$76.9M
FATE icon
37
Fate Therapeutics
FATE
$326M
$157M 0.78%
1,900,000
-1,100,000
-37% -$105M
BABA icon
38
Alibaba
BABA
$308B
$153M 0.76%
676,400
-176,900
-21% -$43.4M
IOVA icon
39
Iovance Biotherapeutics
IOVA
$2.87B
$150M 0.75%
4,750,000
-1,250,000
-21% -$51.8M
MRTX
40
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$146M 0.72%
850,000
-25,000
-3% -$4.95M
LU icon
41
Lufax Holding
LU
$1.3B
$143M 0.71%
2,458,350
+1,118,912
+84% +$68.7M
ASND icon
42
Ascendis Pharma A/S
ASND
$16.8B
$129M 0.64%
1,000,000
– –
QGEN icon
43
Qiagen
QGEN
$8.72B
$124M 0.61%
2,393,874
-677,442
-22% -$37.2M
NYT icon
44
New York Times
NYT
$10.2B
$120M 0.6%
2,379,622
-4,165,707
-64% -$209M
EFX icon
45
Equifax
EFX
$21.4B
$110M 0.55%
606,629
+235,945
+64% +$41.7M
PLYA
46
DELISTED
Playa Hotels & Resorts
PLYA
$109M 0.54%
14,994,867
– –
ALNY icon
47
Alnylam Pharmaceuticals
ALNY
$29.3B
$98.8M 0.49%
700,000
+350,000
+100% +$52.7M
ENTA icon
48
Enanta Pharmaceuticals
ENTA
$400M
$98.4M 0.49%
1,995,000
+220,000
+12% +$11M
HWM icon
49
Howmet Aerospace
HWM
$112B
$95M 0.47%
2,955,729
-1,935,750
-40% -$55.7M
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
$93.3M 0.46%
2,175,000
-100,000
-4% -$4.73M
1
2
3 4 5

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Farallon Capital Management held 257 positions worth $20.1B, up 21% from $16.6B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Farallon Capital Management deployed $2.5B of net new capital in Q1 2021, opening 120 new positions and adding to 40 existing holdings. Its largest new stake was Mastercard: 985,920 shares worth $351M.

By sector, the portfolio is most concentrated in Healthcare at 35% of assets, down from 38% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was New York Times, an estimated $209M trimmed.

  • Farallon Capital Management's largest Q1 2021 buy was Mastercard: 985,920 shares worth $351M.
  • Farallon Capital Management added most to Alexion Pharmaceuticals in Q1 2021, an estimated $546M increase.
  • Farallon Capital Management's biggest Q1 2021 reduction was New York Times, cutting an estimated $209M.
  • Farallon Capital Management fully exited Tiffany & Co. in Q1 2021, selling an estimated $301M.
  • Farallon Capital Management's ten largest holdings make up 33% of its $20.1B portfolio in Q1 2021.
  • Farallon Capital Management opened 120 new positions and closed 20 in Q1 2021.
  • Farallon Capital Management's portfolio value rose 21% quarter-over-quarter to $20.1B.

Based on Farallon Capital Management's 13F filing for Q1 2021, filed 17 May 2021.